Factitious hypoglycemia in insulin-treated diabetic patients

Thierry Galvez,Manuela Lotierzo,Guilhem Conquet,Quentin Verani,Caroline Aguilhon,Isabelle Raingeard,Jean-Paul Cristol,Eric Renard
DOI: https://doi.org/10.1016/j.ando.2023.03.015
Abstract:Factitious hypoglycemia is a factitious disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), referring to intentionally covertly induced hypoglycemia, with potentially severe consequences. Knowledge of factitious hypoglycemia relies on case reports, and evidence-based information and guidelines are lacking. Diagnosing factitious hypoglycemia in insulin-treated diabetic persons is therefore challenging and often requires a long and costly process. Moreover, the typical metrics proposed to differentiate insulin-induced factitious hypoglycemia from insulinoma (i.e., high insulin and low C-peptide versus high insulin and high C-peptide, respectively) are not always applicable, depending on whether the insulin quantification method can detect the insulin analog. When factitious hypoglycemia is suspected, an emerging trend from recent publications advocates a combination of two insulin quantification methods with different cross-reactivity for insulin analogs, early on in the diagnostic process.
What problem does this paper attempt to address?